Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05599191 · ClinicalTrials.gov registry record · Phase 3

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

A Phase 3 study of Cough and Refractory Chronic Cough, sponsored by Bellus Health Inc. - a GSK company.

Active
Registry status
Phase 3
Development phase
825
Enrollment target
20
Study locations

NCT05599191 is a Phase 3 study of Cough and Refractory Chronic Cough that is active but no longer recruiting, run by Bellus Health Inc. - a GSK company. The registered enrollment target is 825 participants, above the 153-participant average among 12 other Cough trials with a reported enrollment target (439% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05599191, a Phase 3 study of Cough and Refractory Chronic Cough, is active but no longer recruiting, sponsored by Bellus Health Inc. - a GSK company.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
825 participants
Enrollment target
20
Study locations

Study Summary

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Conditions Studied

Cough Refractory Chronic Cough

Interventions

  • DRUG Placebo
  • DRUG BLU-5937

Study Locations (20)

Florida

  • GSK Investigational Site - Clearwater
  • GSK Investigational Site - Gainesville
  • GSK Investigational Site - Miami
  • GSK Investigational Site - Miami
  • GSK Investigational Site - Miami
  • GSK Investigational Site - Miami
  • GSK Investigational Site - Orlando

California

  • GSK Investigational Site - Encinitas
  • GSK Investigational Site - Mission Viejo
  • GSK Investigational Site - Paramount
  • GSK Investigational Site - Roseville

Arizona

  • GSK Investigational Site - Litchfield Park
  • GSK Investigational Site - Scottsdale

Colorado

  • GSK Investigational Site - Aurora
  • GSK Investigational Site - Colorado Springs

Illinois

  • GSK Investigational Site - Normal
  • GSK Investigational Site - Oak Lawn

Iowa

  • GSK Investigational Site - Ames
  • GSK Investigational Site - Iowa City

Georgia

  • GSK Investigational Site - Lawrenceville

Trial Details

FieldValue
Enrollment Target 825 participants
Start Date 2022-10-25
Est. Completion 2026-05-28
Phase Phase 3

Sponsor

Bellus Health Inc. - a GSK company

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05599191

The ClinicalTrials.gov registry entry for NCT05599191 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 825 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 153-participant average among 12 other Cough trials with a reported enrollment target (439% higher). The listed sponsor is Bellus Health Inc. - a GSK company, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cough appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05599191 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT05599191 about?

NCT05599191 is a clinical study titled "A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough". This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

What is the current status of trial NCT05599191?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 825 participants. The study started on 2022-10-25. Estimated completion is 2026-05-28.

What conditions does trial NCT05599191 study?

This clinical trial studies the following conditions: Cough, Refractory Chronic Cough.

What interventions are being tested in trial NCT05599191?

The interventions under investigation include: Placebo (DRUG), BLU-5937 (DRUG).

Who is sponsoring clinical trial NCT05599191?

This trial is sponsored by Bellus Health Inc. - a GSK company, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05599191 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cough

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cough

All registered trials for this condition

Refractory Chronic Cough

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.